++
Chapter 4. Pharmacology of Drugs Used in Airway Management
++
++
++
Which of the following is a true statement about the elimination of remifentanil?
++
++
++
A. It is metabolized by hepatic enzymes.
++
++
B. It is primarily removed from the body unchanged by the kidneys.
++
++
C. It is metabolized primarily by plasma and tissue esterases.
++
++
D. It is primarily removed from the body by Hofmann degradation.
++
++
E. It is metabolized primarily by plasma pseudocholinesterases.
+
++
(C) The ester linkage of remifentanil renders it susceptible to cleavage by nonspecific plasma and tissue esterases.
++
++
++
To avoid serious hyperkalemia, which of the following is NOT considered a safe period to administer succinylcholine to a burned patient?
++
++
++
A. immediately after the burn
++
++
B. more than 1 day after the burn
++
++
C. more than 2 days after the burn
++
++
D. more than 3 days after the burn
++
++
E. more than 4 days after the burn
+
++
(E) In burn victims, extrajunctional receptor sensitization becomes clinically significant at 4 to 5 days postburn. It lasts an indefinite period of time, although the “at-risk” period is deemed to have passed at the point healing of the burned area is complete.
++
++
++
Which of the following statements is NOT true about Sugammadex?
++
++
++
A. Sugammadex is a modified g-cyclodextrin.
++
++
B. Sugammadex selectively binds and inactivates vecuronium, enhancing neuromuscular recovery.
++
++
C. Sugammadex selectively binds and inactivates rocuronium, enhancing neuromuscular recovery.
++
++
D. Sugammadex interacts with nicotinic receptors by displacing rocuronium and vecuronium.
++
++
E. Sugammadex does not appear to have any significant hemodynamic or respiratory effects.
+
++
(D) Sugammadex encapsulates and inactivates rocuronium and vecuronium; the resultant complex is excreted in the urine. It does not interact with nicotinic receptors by displacing rocuronium and vecuronium.